JP2023542211A5 - - Google Patents

Info

Publication number
JP2023542211A5
JP2023542211A5 JP2023518391A JP2023518391A JP2023542211A5 JP 2023542211 A5 JP2023542211 A5 JP 2023542211A5 JP 2023518391 A JP2023518391 A JP 2023518391A JP 2023518391 A JP2023518391 A JP 2023518391A JP 2023542211 A5 JP2023542211 A5 JP 2023542211A5
Authority
JP
Japan
Prior art keywords
disease
composition
combination according
disorder
viral vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023518391A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542211A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/071534 external-priority patent/WO2022061378A2/en
Publication of JP2023542211A publication Critical patent/JP2023542211A/ja
Publication of JP2023542211A5 publication Critical patent/JP2023542211A5/ja
Priority to JP2026062800A priority Critical patent/JP2026099946A/ja
Pending legal-status Critical Current

Links

JP2023518391A 2020-09-21 2021-09-21 神経疾患を処置するための方法 Pending JP2023542211A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026062800A JP2026099946A (ja) 2020-09-21 2026-04-06 神経疾患を処置するための方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063080925P 2020-09-21 2020-09-21
US63/080,925 2020-09-21
US202063121152P 2020-12-03 2020-12-03
US63/121,152 2020-12-03
US202163139410P 2021-01-20 2021-01-20
US63/139,410 2021-01-20
US202163140440P 2021-01-22 2021-01-22
US63/140,440 2021-01-22
US202163180407P 2021-04-27 2021-04-27
US63/180,407 2021-04-27
PCT/US2021/071534 WO2022061378A2 (en) 2020-09-21 2021-09-21 Methods for treating neurological disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026062800A Division JP2026099946A (ja) 2020-09-21 2026-04-06 神経疾患を処置するための方法

Publications (2)

Publication Number Publication Date
JP2023542211A JP2023542211A (ja) 2023-10-05
JP2023542211A5 true JP2023542211A5 (cg-RX-API-DMAC7.html) 2024-08-22

Family

ID=80776430

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023518391A Pending JP2023542211A (ja) 2020-09-21 2021-09-21 神経疾患を処置するための方法
JP2026062800A Pending JP2026099946A (ja) 2020-09-21 2026-04-06 神経疾患を処置するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026062800A Pending JP2026099946A (ja) 2020-09-21 2026-04-06 神経疾患を処置するための方法

Country Status (7)

Country Link
US (1) US20230365963A1 (cg-RX-API-DMAC7.html)
EP (1) EP4213891A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023542211A (cg-RX-API-DMAC7.html)
AU (1) AU2021344607A1 (cg-RX-API-DMAC7.html)
CA (1) CA3193406A1 (cg-RX-API-DMAC7.html)
IL (1) IL301525A (cg-RX-API-DMAC7.html)
WO (1) WO2022061378A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023019981A2 (pt) 2021-03-29 2023-12-12 Alnylam Pharmaceuticals Inc Composições do agente irna de huntingtina (htt) e métodos de uso das mesmas
EP4423272A2 (en) * 2021-10-29 2024-09-04 Alnylam Pharmaceuticals, Inc. Huntingtin (htt) irna agent compositions and methods of use thereof
AU2023211606A1 (en) * 2022-01-27 2024-07-11 AskBio Inc. Compositions for treating neurological disease
CN119451703A (zh) * 2022-04-25 2025-02-14 迈特勒公司 髓鞘病症的治疗
WO2024079317A1 (en) * 2022-10-14 2024-04-18 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for the treatment of alpha-synucleinopathies
WO2024149844A1 (en) * 2023-01-12 2024-07-18 Nantes Université Chemically-modified adeno-associated virus

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003288231A1 (en) * 2002-12-13 2004-07-09 Bayer Healthcare Ag Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
ES2582200T3 (es) * 2007-09-12 2016-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilización de vectores víricos portadores del gen CYP46A1 para el tratamiento de la enfermedad de Alzheimer
WO2009149418A2 (en) 2008-06-06 2009-12-10 Asuragen, Inc. Novel compositions for the in vivo delivery of rnai agents
ES2566495T3 (es) * 2010-10-15 2016-04-13 Inserm - Institut National De La Santé Et De La Recherche Médicale Vector de expresión para colesterol 24-hidrolasa en terapia de la enfermedad de Huntington
KR101367568B1 (ko) * 2011-05-31 2014-02-27 임우석 Abc 수송체 조절을 통한 퇴행성신경질환에서 이상단백질 조절
RU2014112958A (ru) 2011-09-21 2015-10-27 Йиссум Ресерч Девелопмент Компани оф де Хебрю Юниверсити оф Джерусалем Лтд. Наносистемы доставки для мирнк
ES2661236T3 (es) 2011-12-13 2018-03-28 Henry Ford Health System Procedimientos, sistemas y composiciones para administración de microARN derivado de células/a base de vesículas
AU2016366549B2 (en) * 2015-12-11 2022-11-10 California Institute Of Technology Targeting peptides for directing adeno-associated viruses (AAVs)
US10457940B2 (en) * 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
KR20180063954A (ko) * 2016-12-02 2018-06-14 서울대학교산학협력단 알츠하이머병 치료를 위한 마이크로RNA-188-5p의 용도
WO2019177550A1 (en) 2018-03-10 2019-09-19 Koc Universitesi Therapeutic nanoparticles containing argonaute for microrna delivery and compositions and methods using same
US20200071699A1 (en) * 2018-08-31 2020-03-05 Ghassan S. Kassab Treatment of alzheimers disease with micro rna and ghrelin
WO2020089154A1 (en) * 2018-10-29 2020-05-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Expression vector for cholesterol 24-hydrolase in therapy of amyotrophic lateral sclerosis

Similar Documents

Publication Publication Date Title
US20250161485A1 (en) Aav capsid variants and uses thereof
KR20240113624A (ko) Aav 캡시드 변이체 및 이의 용도
JP2024045131A (ja) 神経変性疾患の遺伝子治療
KR20250025387A (ko) Aav 캡시드 변이체 및 이의 용도
JP7616995B2 (ja) 神経変性疾患のための遺伝子治療
IL308514B1 (en) Aav treatment of huntington's disease
JP2021522836A5 (cg-RX-API-DMAC7.html)
EP4547690A1 (en) Aav capsid variants and uses thereof
CN115279421A (zh) 用于联合疗法的病毒载体
WO2022061378A2 (en) Methods for treating neurological disease
WO2025038430A1 (en) Aav capsid variants and uses thereof
KR102959609B1 (ko) 안구인두 근이영양증 (opmd) 치료용 조성물 및 방법
WO2024226790A1 (en) Aav capsid variants and uses thereof
JP2025503910A5 (cg-RX-API-DMAC7.html)
JP7854125B2 (ja) 新規なデュアルヘルパープラスミド
US20200283800A1 (en) Gene therapies for neurodegenerative diseases
JP2022548270A5 (cg-RX-API-DMAC7.html)
AU2024253981A1 (en) Compositions and methods for treating cag repeat diseases
JP2026511976A (ja) Dm-1筋強直性ジストロフィーの標的遺伝子療法
KR102839699B1 (ko) 부신척수신경병증의 치료를 위한 abcd1을 코딩하는 핵산 서열의 척추강내 전달
JP2025512709A5 (cg-RX-API-DMAC7.html)
WO2023220719A2 (en) Method for treatment of myotonic dystrophy combining protein expression and rna interference vector delivery with tissue detargeting
JP2025509262A5 (cg-RX-API-DMAC7.html)
JP2023507741A5 (cg-RX-API-DMAC7.html)
JP2022523320A5 (cg-RX-API-DMAC7.html)